Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies.
Liver transplantation cohort
Meta-analysis
Metabolic diseases
NAFLD
Portal vein thrombosis
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
08 Dec 2023
08 Dec 2023
Historique:
accepted:
08
10
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
8
12
2023
Statut:
aheadofprint
Résumé
Portal vein thrombosis (PVT) is a common complication of cirrhosis as a result of portal hypertension and modification in the hemostatic balance. Accumulating evidence now suggests that patients with non-alcoholic fatty liver disease (NAFLD), especially those with advanced forms, have an increased risk of PVT. Hence, we performed a meta-analysis of observational studies to estimate the overall prevalence of PVT in patients with NAFLD and its advanced forms compared with patients with advanced liver diseases from other etiologies. We systematically searched PubMed, Scopus and Web of Science databases from the inception date to December 30th 2022, using predefined keywords, to identify observational studies. Meta-analysis was performed using random-effects modeling. We included five observational studies for a total of 225,571 patients. Of these, 26,840 (11.9%) patients had NAFLD, whereas the PVT prevalence was 8.5% (n = 2,280). When compared with patients with advanced liver diseases from other etiologies, patients with NAFLD and its advanced forms had a higher risk of prevalent PVT (OR 1.34, 100% CI 1.07-1.67 p < 0,01). The between-study heterogeneity was substantial (I
Identifiants
pubmed: 38066387
doi: 10.1007/s11239-023-02912-9
pii: 10.1007/s11239-023-02912-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Fimognari FL, Violi F (2008) Portal vein Thrombosis in liver Cirrhosis. Intern Emerg Med 3:213–218
doi: 10.1007/s11739-008-0128-0
pubmed: 18274708
Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism. Circulation 117:93–102
doi: 10.1161/CIRCULATIONAHA.107.709204
pubmed: 18086925
Mertens I, van Gaal LF (2006) New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J Thromb Haemost 4:1164–1166
doi: 10.1111/j.1538-7836.2006.01919.x
pubmed: 16689783
Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694
doi: 10.1111/j.1538-7836.2005.01204.x
pubmed: 15842354
Targher G et al (2008) NASH predicts plasma inflammatory biomarkers independently of visceral Fat in men. Obesity 16:1394–1399
doi: 10.1038/oby.2008.64
pubmed: 18369343
Cigolini M et al (1996) Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - role of the metabolic syndrome. Thromb Haemost 76:69–73
doi: 10.1055/s-0038-1650524
pubmed: 8819254
Beavers CJ, Heron P, Smyth SS, Bain JA, Macaulay TE (2015) Obesity and antiplatelets-does one size fit all? Thromb Res 136:712–716
doi: 10.1016/j.thromres.2015.07.015
pubmed: 26205154
Coban E, Ozdogan M (2005) The mean platelet volume in patients with obesity. Int J Clin Pract 59:981–982
doi: 10.1111/j.1742-1241.2005.00500.x
pubmed: 16033624
Abdel-Razik A et al (2021) De novo Portal Vein Thrombosis in Non-Cirrhotic Non-Alcoholic Fatty Liver Disease: A 9-Year Prospective Cohort Study. Front Med (Lausanne) 8:650818
doi: 10.3389/fmed.2021.650818
pubmed: 33996858
DeLeeuw P et al (2022) Pre-transplant portal vein thrombosis in non-alcoholic fatty liver disease patients—pathogenesis, risk factors, and implications on management. Transl Gastroenterol Hepatol 7:27
doi: 10.21037/tgh-19-361
pubmed: 35892050
pmcid: 9257532
Stroup DF et al (2000) Meta-analysis of Observational studies in Epidemiology: a proposal for reporting. JAMA 283:2008–2012
doi: 10.1001/jama.283.15.2008
pubmed: 10789670
Agbim U et al (2019) Impact of nonmalignant portal vein Thrombosis in transplant recipients with nonalcoholic steatohepatitis. Liver Transpl 25:68–78
doi: 10.1002/lt.25322
pubmed: 30091296
Li J, Wang Q, Yang M et al (2022) Metabolic disorders and risk of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Turk J Gastroenterol 33(7):541
pubmed: 35879911
pmcid: 9404680
Li J, Wang Q, Yang M, Sun X (2022) Metabolic disorders and risk of portal vein Thrombosis in liver Cirrhosis: a systematic review and Meta-analysis. Turk J Gastroenterol 33:541–553
doi: 10.5152/tjg.2022.211022
pubmed: 35879911
pmcid: 9404680
Ghabril M et al (2016) Portal vein Thrombosis is a risk factor for poor early outcomes after liver transplantation: analysis of risk factors and outcomes for portal vein Thrombosis in Waitlisted patients. Transplantation 100:126–133
doi: 10.1097/TP.0000000000000785
pubmed: 26050013
Stine JG et al (2017) Advanced non-alcoholic steatohepatitis Cirrhosis: a high-risk population for pre-liver transplant portal vein Thrombosis. World J Hepatol 9:139–146
doi: 10.4254/wjh.v9.i3.139
pubmed: 28217250
pmcid: 5295147
Montenovo MI, Rahnemai-Azar A, Reyes J, Perkins J (2018) Clinical impact and risk factors of portal vein Thrombosis for patients on wait list for liver transplant. Exp Clin Transplant 16:166–171
pubmed: 28621635
Eshraghian A et al (2018) Portal vein thrombosis in patients with liver cirrhosis and its impact on early and long-term outcomes after liver transplantation. Int J Clin Pract 73:e13309
doi: 10.1111/ijcp.13309
Molinari M et al (2021) Portal vein Thrombosis and renal dysfunction: a national comparative study of liver transplant recipients for NAFLD versus alcoholic Cirrhosis. Transpl Int 34:1105–1122
doi: 10.1111/tri.13873
pubmed: 33780554